視網膜疾病藥物市場規模、佔有率、成長分析（按疾病、疾病類型、治療技術、給藥途徑、最終用戶和地區）- 產業預測，2025 年至 2032 年

預計 2022 年全球視網膜疾病治療市場價值將達到 118 億美元，到 2031 年將成長至 256.3 億美元，預測期內（2024-2031 年）的複合年成長率為 9.0%。

全球視網膜疾病治療市場正經歷顯著成長，這主要得益於視網膜疾病盛行率的不斷上升，目前全球超過2.53億人受其困擾。這個日益嚴重的問題給醫療保健系統帶來了越來越大的壓力，尤其是在老齡化社會持續擴大、視力障礙主要集中在50歲以上人群的情況下。視網膜疾病盛行率的上升，加上糖尿病盛行率的上升，尤其是在新興市場，進一步加劇了這項挑戰。然而，隨著專門從事視網膜疾病治療的專業醫療保健專業人員的湧入以及各國報銷體系的加強，預計市場將受益，這將為更廣泛地獲得先進的視網膜治療療法和創新的解決方案鋪平道路。

目錄

介紹

• 調查目標
• 調查範圍
• 定義

調查方法

• 資訊收集
• 二次資料和一次資料方法
• 市場規模預測
• 市場假設與約束

執行摘要

• 全球市場展望
• 供需趨勢分析
• 細分機會分析

市場動態與展望

• 市場概覽
• 市場規模
• 市場動態
  • 促進因素和機會
  • 限制與挑戰
• 波特的分析

關鍵市場考察

• 關鍵成功因素
• 競爭程度
• 關鍵投資機會
• 市場生態系統
• 市場吸引力指數（2023年）
• PESTEL分析
• 總體經濟指標
• 價值鏈分析
• 定價分析

視網膜疾病治療市場規模（依疾病類型分類）及複合年成長率（2024-2031）

• 市場概覽
• 黃斑部病變
• 糖尿病眼科疾病
• 視網膜剝離
• 視網膜母細胞瘤
• 黃斑皺紋
• 黃斑裂孔
• 漂浮物

視網膜疾病治療藥物市場規模（依疾病類型及複合年成長率）（2024-2031）

• 市場概覽
• 遺傳學
• 年齡

視網膜疾病藥物市場規模（依治療技術及複合年成長率） (2024-2031)

• 市場概覽
• 雷射
• 冷凍
• 植入
• 縮排
• 氣動視網膜固定術
• 鞏膜扣帶術
• 玻璃體切除手術

視網膜疾病治療市場規模（依給藥途徑及複合年成長率）（2024-2031）

• 市場概覽
• 口服
• 外用
• 玻璃體內注射
• 其他

視網膜疾病治療藥物市場規模（按最終用戶和複合年成長率分類）（2024 年至 2031 年）

• 市場概覽
• 醫院
• 門診手術中心
• 家庭醫療保健
• 其他

視網膜疾病治療市場規模（依通路及複合年成長率）（2024-2031）

• 市場概覽
• 直接競標
• 醫院藥房
• 零售藥局
• 網路藥局
• 其他

視網膜疾病治療藥物市場規模（按地區）及複合年成長率（2024-2031）

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲國家地區
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 其他亞太地區
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲地區
• 中東和非洲
  • 海灣合作理事會國家
  • 南非
  • 其他中東和非洲地區

競爭資訊

• 前五大公司對比
• 主要企業市場定位（2023年）
• 主要市場參與者所採取的策略
• 近期市場趨勢
• 公司市場佔有率分析（2023年）
• 主要企業簡介
  • 公司詳情
  • 產品系列分析
  • 按部門分類的公司佔有率分析
  • 收益年比比較（2021-2023年）

主要企業簡介

• Regeneron Pharmaceuticals, Inc.（USA）
• Roche Holding AG（Switzerland）
• Novartis AG（Switzerland）
• Allergan（part of AbbVie）（USA）
• Bayer AG（Germany）
• Oculis（Switzerland）
• REGENXBIO Inc.（USA）
• Adverum Biotechnologies, Inc.（USA）
• Kodiak Sciences Inc.（USA）
• EyePoint Pharmaceuticals, Inc.（USA）
• Apellis Pharmaceuticals, Inc.（USA）
• Iveric Bio, Inc.（USA）（Acquired by Astellas）
• Annexon Biosciences（USA）
• Hemera Biosciences（USA）（Acquired by Roche）
• Gyroscope Therapeutics（UK）（Acquired by Novartis）
• Graybug Vision, Inc.（USA）
• Clearside Biomedical, Inc.（USA）
• Ocuphire Pharma, Inc.（USA）
• Lineage Cell Therapeutics, Inc.（USA）
• Ocugen, Inc.（USA）

結論和建議

Global Retinal Disease Therapeutics Market size was valued at USD 11.8 billion in 2022 and is poised to grow from USD 12.86 billion in 2023 to USD 25.63 billion by 2031, growing at a CAGR of 9.0% during the forecast period (2024-2031).

The global retinal disease therapeutics market is experiencing significant growth, driven by the rising prevalence of retinal disorders, which currently affect over 253 million individuals worldwide. This burgeoning issue is putting increasing pressure on healthcare systems, particularly as the aging population continues to expand, with a notable concentration of vision impairment among those over 50 years old. The escalating incidence of retinal diseases, especially in the context of rising diabetes rates in emerging markets, is further compounding the challenge. However, the market is projected to benefit from an influx of specialized healthcare professionals dedicated to retinal disease treatment and enhanced reimbursement frameworks in multiple countries, paving the way for expanding access to advanced therapies and innovative solutions in retinal care.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Retinal Disease Therapeutics market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Retinal Disease Therapeutics Market Segments Analysis

Global Retinal Disease Therapeutics Market is segmented by disorder, disorder type, treatment techniques, route of administration, end-users, distribution channel and region. Based on disorder, the market is segmented into macular degeneration, diabetic eye disease, retinal detachment, retinoblastoma, macular pucker, macular hole and floaters. Based on disorder type, the market is segmented into genetic and age related. Based on treatment techniques, the market is segmented into laser, freezing, implanting, indenting, pneumatic retinopexy, scleral buckling and vitrectomy. Based on route of administration, the market is segmented into oral, topical, intravitreal and others. Based on end-users, the market is segmented into hospitals, ambulatory surgical centers, home healthcare and others. Based on distribution channel, the market is segmented into direct tender, hospital pharmacy, retail pharmacy, online pharmacy and others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Retinal Disease Therapeutics Market

The increasing incidence of eye-related disorders, particularly in more developed nations, is a significant factor propelling the global market for retinal disease therapeutics. A substantial number of individuals worldwide experience conditions such as diabetic retinopathy and age-related macular degeneration (AMD), underscoring the urgent need for effective treatments. As more individuals become aware of these conditions through enhanced health education initiatives, particularly in developing areas, there is a greater emphasis on seeking early intervention to avoid vision loss. This growing awareness and demand for innovative therapeutic solutions are anticipated to further stimulate advancements and expansion within the retinal therapeutics market.

Restraints in the Global Retinal Disease Therapeutics Market

The global retinal disease therapeutics market faces several challenges that may hinder its growth. High expenses associated with retinal treatment therapies can limit patient accessibility and adoption. Moreover, patients often report experiencing short-term side effects, along with potential long-term complications like infections and inflammation following procedures such as laser eye surgery. The risk of unintentional scleral perforation during specific surgical techniques, such as pneumatic retinopexy, may further deter patient willingness to undergo treatment. Additionally, inadequate healthcare infrastructure in developing regions poses a significant obstacle to the advancement of the retinal disease therapeutics market.

Market Trends of the Global Retinal Disease Therapeutics Market

The Global Retinal Disease Therapeutics market is poised for significant growth, driven by the emergence of advanced technologies, particularly in retinal gene therapy. Innovations such as Luxturna, which targets the RPE65 gene mutation to treat inherited conditions like Leber's congenital amaurosis, underline a transformative shift in therapeutic approaches. As several promising retinal gene therapies are currently undergoing clinical trials using recombinant viruses, their anticipated approval and market entry are set to further enhance treatment options. Between 2022 and 2028, this advancement in gene therapy is projected to significantly expand the market, catering to the increasing demand for effective solutions for retinal disorders.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2023
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis

Global Retinal Disease Therapeutics Market Size by Disorder & CAGR (2024-2031)

• Market Overview
• Macular Degeneration
• Diabetic Eye Disease
• Retinal Detachment
• Retinoblastoma
• Macular Pucker
• Macular Hole
• Floaters

Global Retinal Disease Therapeutics Market Size by Disorder Type & CAGR (2024-2031)

• Market Overview
• Genetic
• Age Related

Global Retinal Disease Therapeutics Market Size by Treatment Techniques & CAGR (2024-2031)

• Market Overview
• Laser
• Freezing
• Implanting
• Indenting
• Pneumatic Retinopexy
• Scleral Buckling
• Vitrectomy

Global Retinal Disease Therapeutics Market Size by Route Of Administration & CAGR (2024-2031)

• Market Overview
• Oral
• Topical
• Intravitreal
• Others

Global Retinal Disease Therapeutics Market Size by End-Users & CAGR (2024-2031)

• Market Overview
• Hospitals
• Ambulatory Surgical Centers
• Home Healthcare
• Others

Global Retinal Disease Therapeutics Market Size by Distribution Channel & CAGR (2024-2031)

• Market Overview
• Direct Tender
• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy
• Others

Global Retinal Disease Therapeutics Market Size & CAGR (2024-2031)

• North America (Disorder, Disorder Type, Treatment Techniques, Route Of Administration, End-Users, Distribution Channel)
  • US
  • Canada
• Europe (Disorder, Disorder Type, Treatment Techniques, Route Of Administration, End-Users, Distribution Channel)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Disorder, Disorder Type, Treatment Techniques, Route Of Administration, End-Users, Distribution Channel)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Disorder, Disorder Type, Treatment Techniques, Route Of Administration, End-Users, Distribution Channel)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Disorder, Disorder Type, Treatment Techniques, Route Of Administration, End-Users, Distribution Channel)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2023
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2023
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2021-2023)

Key Company Profiles

• Regeneron Pharmaceuticals, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Roche Holding AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Allergan (part of AbbVie) (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bayer AG (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Oculis (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• REGENXBIO Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Adverum Biotechnologies, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Kodiak Sciences Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• EyePoint Pharmaceuticals, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Apellis Pharmaceuticals, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Iveric Bio, Inc. (USA) (Acquired by Astellas)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Annexon Biosciences (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Hemera Biosciences (USA) (Acquired by Roche)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Gyroscope Therapeutics (UK) (Acquired by Novartis)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Graybug Vision, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Clearside Biomedical, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Ocuphire Pharma, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Lineage Cell Therapeutics, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Ocugen, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations